fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

GLP-1 RAs – where are we now? What have we learned?

Written by | 17 Mar 2025

Pharmacist Deborah Evans runs a weight-management clinic at Remedi Health in Winchester. She has helped many people to lose weight and improve their health using the GLP-1 receptor… read more.

Taking semaglutide before bariatric surgery does not improve weight loss or safety

Written by | 15 Mar 2025

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy… read more.

Semaglutide shows promise in reducing cravings for alcohol, heavy drinking

Written by | 14 Feb 2025

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research… read more.

Novo Nordisk announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous semaglutide 7.2 mg for obesity

Written by | 22 Jan 2025

Novo Nordisk  announced headline results from STEP UP, a phase IIIb trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous… read more.

Semaglutide might reduce the risk of Alzheimer’s disease

Written by | 25 Oct 2024

Researchers report that patients treated with semaglutide have achieved a significantly lower risk of developing Alzheimer’s disease compared to those exposed to seven other anti-diabetic medications, including other… read more.

Survey shows 25% of adults consider weight loss drug use without prescription

Written by | 23 Sep 2024

Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is… read more.

Semaglutide and tirzepatide treatment leads to weight loss in type 1 diabetes

Written by | 14 Sep 2024

Treatment with semaglutide and tirzepatide led to significant weight loss and improved blood sugar control in overweight or obese patients with type 1 diabetes (T1D). Researchers reported this… read more.

Innovative semaglutide hydrogel could reduce diabetes shots to once a month

Written by | 10 Sep 2024

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once… read more.

High BMI eligibility for semaglutide could cost Medicare an additional $145 billion annually

Written by | 30 Aug 2024

A brief research report found that 61% of Medicare-eligible adults have a BMI of 27 or higher, which means they may benefit from a GLP-1 receptor agonist like… read more.

Semaglutide may show promise for smoking cessation

Written by | 5 Aug 2024

New use of semaglutide was associated with a lower risk for medical care related to tobacco use disorder (TUD) in smokers with type 2 diabetes compared with 7… read more.

Data shows surge in in new GLP-1RA prescriptions for obesity without type 2 diabetes

Written by | 25 Jul 2024

A nationwide study found a marked increase in new GLP-1RA prescriptions over the last decade, particularly since 2020. Semaglutide was the most prescribed GLP-1RA, by far, in 2023…. read more.

Popular prescription weight loss drugs linked to uncommon blinding condition

Written by | 14 Jul 2024

A new study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.